Integrated Biopharma, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  June 13, 2005

Integrated BioPharma, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

000-28876   22-2407475
(Commission File Number)    (IRS Employer Identification No.)
     
225 Long Avenue    
Hillside, New Jersey   07205
(Address of Principal Executive Offices)        (Zip Code)
     
(973) 926-0816
    (Registrant’s Telephone Number, Including Area Code)
     
     

(Former Name or Former Address, if Changed Since Last Report)

 

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  |_|   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  |_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  |_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  |_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

On June 13, 2005, Integrated BioPharma, Inc. released an investor relations presentation. The document is attached as an exhibit to this Report.

Item 9.01. Financial Statements and Exhibits

(c)     Exhibits.

Exhibit No.           Description

99.1                     Investor Relations Presentation issued by Integrated BioPharma, Inc. on June 13, 2005.

1

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

 

                                                                                        INTEGRATED BIOPHARMA, INC.
Date: June 13, 2005                                                         By: /s/ Gregory A. Gould
                                                                                        Gregory A. Gould
                                                                                         Senior Vice President and Chief Financial Officer